* Evofem Biosciences Inc EVFM.OQ EVFM.O is expected
to show a
rise in quarterly revenue when it reports results on March 3.
* The San Diego California-based company is expected to
report a
1,898.0% increase in revenue to $3.357 million from $168
thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Evofem Biosciences
Inc is
for a loss of 23 cents per share. For the same quarter last
year, the company reported a loss of 50 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Evofem
Biosciences Inc is $2, about 75.1% above its last closing
price of $0.50.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.30 -0.29 -0.48 Missed -62.7
Jun. 30 2021 -0.37 -0.37 -0.27 Beat 26.5
Mar. 31 2021 -0.49 -0.49 -0.56 Missed -14.9
Dec. 31 2020 -0.40 -0.36 -0.50 Missed -37.9
Sep. -0.44 -0.44 -0.37 Beat 15.9
30 2020
Jun. 30 2020 -0.37 -0.37 -0.91 Missed -143.8
Mar. 31 2020 -0.33 -0.32 -0.40 Missed -25
Dec. 31 2019 -0.28 -0.29 -0.27 Beat 6.3
This summary was machine generated March 1 at 22:49 GMT. All
figures in US dollars unless otherwise stated